替瑞利尤单抗联合阿替利珠单抗和贝伐珠单抗治疗不可切除局部晚期或转移性肝细胞癌(MORPHEUS-Liver):一项随机、开放标签、1b-2期研究
MORPHEUS-Liver研究在26个中心随机分配59例既往未治疗的不可切除肝细胞癌患者(2:1)接受替瑞利尤单抗+阿替利珠单抗+贝伐珠单抗(n=41)或阿替利珠单抗+贝伐珠单抗(n=18)。替瑞利尤单抗组确认客观缓解率为43%(95%CI 27-59),对照组为11%(95%CI 1-35)。作者认为加用替瑞利尤单抗可能更具临床活性,需进一步研究。
要点
- 替瑞利尤单抗+阿替利珠单抗+贝伐珠单抗组确认客观缓解率43%(95%CI 27-59),对照组11%(95%CI 1-35)。
- 两组所有患者均发生不良事件,瘙痒、关节痛和腹泻在替瑞利尤单抗组发生率更高,但主要为1-2级。
- 替瑞利尤单抗组治疗相关死亡1例(胆汁淤积),对照组2例(食管静脉曲张出血和上消化道出血)。
核心结论
- 这项信号探索性研究提示,在阿替利珠单抗和贝伐珠单抗基础上加用替瑞利尤单抗可能比单用阿替利珠单抗联合贝伐珠单抗在不可切除肝细胞癌中更具临床活性。
- 基于这些数据,有必要进一步研究替瑞利尤单抗联合阿替利珠单抗和贝伐珠单抗。
研究设计与样本
- 这项随机、开放标签、1b-2期伞式研究在中国、法国、以色列、新西兰、韩国、中国台湾和美国共26个中心开展。
- 纳入年龄≥18岁、既往未治疗的局部晚期不可切除肝细胞癌、ECOG体能状态0-1、Child-Pugh A级、预期寿命至少3个月的患者。
- 采用置换区组随机化按2:1分配接受替瑞利尤单抗600 mg+阿替利珠单抗1200 mg+贝伐珠单抗15 mg/kg或阿替利珠单抗1200 mg+贝伐珠单抗15 mg/kg,每3周第1天静脉输注,每21天为一周期。
- 2020年8月20日至2022年2月10日评估154例患者合格性,随机分配59例:替瑞利尤单抗+阿替利珠单抗+贝伐珠单抗组41例,阿替利珠单抗+贝伐珠单抗组18例;替瑞利尤单抗组1例在未接受任何治疗前发生不良事件并退出研究。
- 主要终点为客观缓解率,临床活性在疗效可评估人群(接受至少一剂各 assigned 方案药物的所有患者)中分析,安全性在所有接受任何研究治疗的患者中评估。
主要发现
- 中位年龄65.0岁(IQR 61.0-73.0);58例患者中男性46例(79%),女性12例(21%);大多数患者为亚洲人(23例[40%])或白人(21例[36%])。
- 截至临床 cutoff(2023年8月21日),替瑞利尤单抗+阿替利珠单抗+贝伐珠单抗组中位随访20.6个月(IQR 10.6-28.0),阿替利珠单抗+贝伐珠单抗组14.0个月(IQR 4.2-18.5)。
- 确认客观缓解率在替瑞利尤单抗+阿替利珠单抗+贝伐珠单抗组为43%(95%CI 27-59,n=17),在阿替利珠单抗+贝伐珠单抗组为11%(95%CI 1-35,n=2)。
- 两组所有患者均发生不良事件;瘙痒(替瑞利尤单抗组20/40例[50%] vs 对照组3/18例[17%])、关节痛(13/40例[33%] vs 2/18例[11%])和腹泻(12/40例[30%] vs 1/18例[6%])在替瑞利尤单抗+阿替利珠单抗+贝伐珠单抗组发生率明显更高,但主要为1-2级。
- 最常见的3-4级不良事件为高血压(替瑞利尤单抗组6/40例[15%] vs 对照组2/18例[11%])、天冬氨酸氨基转移酶升高(3/40例[8%] vs 1/18例[6%])和蛋白尿(2/40例[5%] vs 2/18例[11%]);严重不良事件在替瑞利尤单抗组21/40例(53%),对照组10/18例(56%);治疗相关死亡在替瑞利尤单抗组1例(胆汁淤积),对照组2例(食管静脉曲张出血和上消化道出血)。
关键数值与推荐
- 替瑞利尤单抗+阿替利珠单抗+贝伐珠单抗组确认客观缓解率43%(95%CI 27-59,n=17)。
- 阿替利珠单抗+贝伐珠单抗组确认客观缓解率11%(95%CI 1-35,n=2)。
- 替瑞利尤单抗+阿替利珠单抗+贝伐珠单抗组中位随访20.6个月(IQR 10.6-28.0),阿替利珠单抗+贝伐珠单抗组14.0个月(IQR 4.2-18.5)。
临床怎么用
- 作者认为,在阿替利珠单抗和贝伐珠单抗基础上加用替瑞利尤单抗可能比单用阿替利珠单抗联合贝伐珠单抗在不可切除肝细胞癌中更具临床活性。
- 作者建议,基于这些数据,有必要进一步研究替瑞利尤单抗联合阿替利珠单抗和贝伐珠单抗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: PD-L1 and VEGF blockade with atezolizumab plus bevacizumab has been shown to improve survival in unresectable hepatocellular carcinoma. TIGIT is an immune checkpoint regulator implicated in many cancers, including unresectable hepatocellular carcinoma. Here, we evaluate the clinical activity and safety of the addition of tiragolumab, an anti-TIGIT monoclonal antibody, to atezolizumab plus bevacizumab. METHODS: This randomised, open-label, phase 1b-2 umbrella study was conducted at 26 centres across China, France, Israel, New Zealand, South Korea, Taiwan, and the USA. Eligible patients were adults aged 18 years old or older with previously untreated locally advanced unresectable hepatocellular carcinoma, an Eastern Cooperative Oncology Group performance status of 0-1, Child-Pugh class A disease, and a life expectancy of at least 3 months. Eligible patients were randomly assigned (2:1) using permuted block randomisation to receive either tiragolumab 600 mg plus atezolizumab 1200 mg plus bevacizumab 15 mg/kg or atezolizumab 1200 mg plus bevacizumab 15 mg/kg, administered via intravenous infusion every 3 weeks on day 1 of each 21-day cycle. Patients received treatment until unacceptable toxic effects or loss of clinical benefit, whichever occurred first. The primary endpoint was objective response rate. Analysis of clinical activity was done in the efficacy-evaluable population (all patients who received at least one dose of each drug for their assigned treatment regimen) and safety was assessed in all patients who received any study treatment. The trial is registered with ClinicalTrials.gov, NCT04524871, and is ongoing. FINDINGS: Between Aug 20, 2020, and Feb 10, 2022, we assessed 154 patients for eligibility and 59 eligible patients were randomly assigned to receive tiragolumab plus atezolizumab plus bevacizumab (n=41) or atezolizumab plus bevacizumab (n=18); one patient in the tiragolumab plus atezolizumab plus bevacizumab group experienced an adverse event before receiving any treatment and withdrew from the study. Median age was 65·0 years (IQR 61·0-73·0). 46 (79%) of 58 patients were male and 12 (21%) were female. Most patients were Asian (23 [40%]) or White (21 [36%]). At the time of clinical cutoff (Aug 21, 2023), median follow-up was 20·6 months (IQR 10·6-28·0) in the tiragolumab plus atezolizumab plus bevacizumab group and 14·0 months (4·2-18·5) in the atezolizumab plus bevacizumab group. The confirmed objective response rate was 43% (95% CI 27-59, n=17) in the tiragolumab plus atezolizumab plus bevacizumab group and 11% (1-35, n=2) in the atezolizumab plus bevacizumab group. All patients in both groups experienced an adverse event. The incidence of pruritis (20 [50%] of 40 patients vs three [17%] of 18 patients), arthralgia (13 [33%] vs two [11%]), and diarrhoea (12 [30%] vs one [6%]) was notably higher in the tiragolumab plus atezolizumab plus bevacizumab group than in the atezolizumab plus bevacizumab group, although these were mainly grade 1-2. The most common grade 3-4 adverse events were hypertension (six [15%] of 40 patients in the tiragolumab plus atezolizumab plus bevacizumab group vs two [11%] of 18 patients in the atezolizumab plus bevacizumab group), aspartate aminotransferase increased (three [8%] of 40 patients vs one [6%] of 18 patients), and proteinuria (two [5%] of 40 patients vs two [11%] of 18 patients). Serious adverse events occurred in 21 (53%) of 40 patients in the tiragolumab plus atezolizumab plus bevacizumab group and in ten (56%) of 18 patients in the atezolizumab plus bevacizumab group. Treatment-related deaths occurred in one patient in the tiragolumab plus atezolizumab plus bevacizumab group (due to cholestasis) and two patients in the atezolizumab plus bevacizumab group (due to oesophageal varices haemorrhage and upper gastrointestinal haemorrhage). The addition of tiragolumab to atezolizumab plus bevacizumab did not appear to result in a substantial worsening of treatment-related or immune-mediated adverse events, and no new safety signals were identified. INTERPRETATION: This signal-seeking study suggests that the addition of tiragolumab to atezolizumab and bevacizumab might be more clinically active than atezolizumab plus bevacizumab alone in unresectable hepatocellular carcinoma. Based on these data, further study of combination tiragolumab plus atezolizumab plus bevacizumab is warranted. FUNDING: F Hoffmann-La Roche and Genentech.
引用
- Finn RS, Ryoo BY, Hsu CH, et al. Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study. Lancet Oncol. 2025. PMID: 39855251. doi:10.1016/S1470-2045(24)00679-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。